Compass Therapeutics (CMPX) Operating Expenses (2023 - 2025)
Historic Operating Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $15.8 million.
- Compass Therapeutics' Operating Expenses rose 2923.44% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 2686.82%. This contributed to the annual value of $57.5 million for FY2024, which is 1412.15% up from last year.
- As of Q3 2025, Compass Therapeutics' Operating Expenses stood at $15.8 million, which was up 2923.44% from $21.1 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Operating Expenses high stood at $21.1 million for Q2 2025, and its period low was $9.7 million during Q1 2023.
- In the last 3 years, Compass Therapeutics' Operating Expenses had a median value of $15.4 million in 2023 and averaged $14.8 million.
- In the last 5 years, Compass Therapeutics' Operating Expenses skyrocketed by 262.45% in 2024 and then soared by 4068.91% in 2025.
- Over the past 3 years, Compass Therapeutics' Operating Expenses (Quarter) stood at $15.4 million in 2023, then grew by 7.67% to $16.6 million in 2024, then fell by 4.57% to $15.8 million in 2025.
- Its Operating Expenses was $15.8 million in Q3 2025, compared to $21.1 million in Q2 2025 and $18.0 million in Q1 2025.